EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Experiences of metastatic prostate cancer patients with a mainstream genetic testing pathway

Michiel Vlaming iD, Eveline M A Bleiker, Gina Schijven, Lambertus A L M Kiemeney, Harm H E van Melick, Jarmo C B Hunting, M Arjen Noordzij, Aart Beeker, Diederik M Somford, Henk G van der Poel, Carl J Wijburg, Bart P Wijsman und 10 weitere

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70194 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Michiel Vlaming und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division Laboratories, Pharmacy and Biomedical Genetics, Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Genetic Testing. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: KWF Kankerbestrijding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with metastatic prostate cancer (mPCa) are eligible for germline genetic testing. This study assessed the experiences of mPCa patients undergoing genetic testing after being counselled by non‐genetic healthcare professionals (ngHCPs: urologists, oncologists, nurses). We assessed the psychosocial impact, decision‐making difficulties and knowledge of genetics. In a prospective cohort study across 15 hospitals in the Netherlands, genetic testing was discussed and requested by ngHCPs. Patients completed questionnaires shortly after receiving pre‐test genetic counselling and 4 weeks and 6 months after receiving their genetic test results. Anxiety, depression, distress, decisional conflict regarding genetic testing, decision regret and knowledge of genetics were assessed. Of 767 patients who received germline genetic testing, 5% to 8% experienced clinically significant anxiety or depression at some point in time. Although up to 49% of participants had significantly elevated distress scores as assessed with the Distress Thermometer, more than 90% stated that the testing process did not affect their feelings of distress. Patients with high educational levels had more favourable outcomes than patients with low educational levels on distress and decisional conflict (odds ratios 0.36 [0.23–0.57] and 0.44 [0.21–0.93], respectively). Furthermore, only 50% of the knowledge questions about genetics were answered correctly. To conclude, germline genetic testing within a mainstreaming pathway does not lead to increased levels of general anxiety or depression in most mPCa patients. However, the poorer outcomes on several psychosocial measures for patients with low educational levels are a point of concern.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsGenetic TestingHumansMaleMiddle AgedAgedProspective StudiesGenetic CounselingDecision MakingSurveys and QuestionnairesAnxietyNetherlandsNeoplasm MetastasisDepressionHealth Knowledge, Attitudes, Practice

Stichwörter der Autor:innen

genetic testinggermlinemainstreammetastatic prostate cancerpsychosocial

Autor:innen und Institutionen

  • Division Laboratories, Pharmacy and Biomedical Genetics, Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Clinical Genetics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Science Department IQ Health, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.

ORCID-Profile: Michiel Vlaming

Förderung

  • KWF Kankerbestrijding

Zitieren

APA

Vlaming, M., Bleiker, E. M. A., Schijven, G., Kiemeney, L. A. L. M., van Melick, H. H. E., Hunting, J. C. B., Noordzij, M. A., Beeker, A., Somford, D. M., van der Poel, H. G., Wijburg, C. J., Wijsman, B. P., Hoekstra, R. J., van Moorselaar, R. J. A., van Bezooijen, B. P. J., Meijer, R. P., Busstra, M. B., van den Berg, H. P., Robbrecht, D. G. J., …, & Ausems, M. G. E. M. (2026). Experiences of metastatic prostate cancer patients with a mainstream genetic testing pathway. International Journal of Cancer. https://doi.org/10.1002/ijc.70194

Vancouver

Vlaming M, Bleiker EMA, Schijven G, Kiemeney LALM, van Melick HHE, Hunting JCB, et al. Experiences of metastatic prostate cancer patients with a mainstream genetic testing pathway. International Journal of Cancer. 2026. doi:10.1002/ijc.70194

BibTeX
@article{Vlaming2026,
  author = {Vlaming, Michiel and Bleiker, Eveline M A and Schijven, Gina and Kiemeney, Lambertus A L M and van Melick, Harm H E and Hunting, Jarmo C B and Noordzij, M Arjen and Beeker, Aart and Somford, Diederik M and van der Poel, Henk G and Wijburg, Carl J and Wijsman, Bart P and Hoekstra, Robert J and van Moorselaar, R Jeroen A and van Bezooijen, Bart P J and Meijer, Richard P and Busstra, Martijn B and van den Berg, H Pieter and Robbrecht, Debbie G J and Doornweerd, Benjamin H J and van Oort, Inge M and Ausems, Margreet G E M},
  title = {Experiences of metastatic prostate cancer patients with a mainstream genetic testing pathway},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70194}
}
Kostenlos starten →